Article: B-M S and Otsuka launch Abilify Discmelt.(Bristol-Myers Squibb and Otsuka Pharmaceutical Co product introduction )(Brief article)

US drugmaker Bristol-Myers Squibb and Japan's Otsuka Pharmaceutical have announced the launch of an orally disintegrating tablet version of their co-developed antipsychotic Abilify (arpiprazol), known as Abilify Discmelt. This follows the US Food and Drug Administration approval of the product in June this year.

The firms explained that the product, which is a vanilla flavored tablet, available in 10mg and 15mg dosages, was designed as a convenient alternative for schizophrenic ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!